Table 1.

Attributes and levels

Attributes	Levels
Efficacy
Cure rate	95%; 97%; 100%
Convenience
Once-daily tablet count and packaging	1 tablet from a prescription bottle 1 tablet in a single-dose blister pack 3 tablets in a single-dose blister pack
Duration of treatment (weeks)	8; 12; 16; 24
Office visits for HCV treatment (all patients required to have 1 visit for treatment initiation and 1 visit for post-treatment viral evaluation)	Simplified monitoring during HCV treatment (e.g., telephone check-in by doctor or nurse) One additional office visit during HCV treatment Two additional office visits during HCV treatment
Co-therapy management
Modification of concurrent statin usea	No modification to a statin Temporarily reduce dose of a statin Temporarily stop taking a statin Switch to a different medication
Modification of concurrent PPI useb	No modification to a PPI Temporarily reduce dose or modify timing of taking a PPI Temporarily stop taking a PPI Switch to a different medication
Mild common side effects
Risk of diarrhea	5%; 15%; 25%
Risk of headache	5%; 15%; 25%; 35%
Risk of nausea	5%; 15%; 25%

HCV hepatitis C virus, PPI proton pump inhibitor

^aThe levels “temporarily reduce dose of a statin” and “temporarily stop taking a statin” were pooled in the analysis, as they both reflect similar, temporary modifications of use

^bThe levels “temporarily reduce dose or modify timing of taking a PPI” and “temporarily stop taking a PPI” were pooled in the analysis, as they both reflect similar temporary modifications of use